{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:35:23Z","timestamp":1789972523944,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006533","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T00:00:00Z","timestamp":1350432000000}}],"reference-count":139,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006533.pub2","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T16:58:56Z","timestamp":1349974736000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Duloxetine versus other anti-depressive agents for depression"],"prefix":"10.1002","volume":"2012","author":[{"given":"Andrea","family":"Cipriani","sequence":"first","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry ll; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany D-89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 601-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Nos\u00e8","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Medicine and Public Health, Section of Psychiatry; Policlinico \"G.B.Rossi\" Pzz.le L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Purgato","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro M","family":"Omori","sequence":"additional","affiliation":[{"name":"Toyokawa City Hospital; Department of Psychiatry; Koumei 1-19 Toyokawa Aichi Japan 442-8561"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Trespidi","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.08m04592","article-title":"Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study","volume":"70","author":"Cutler","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Europen Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0003|cit3","unstructured":"Eli Lilly Trial Duloxetine versus placebo and paroxetine in the treatment of major depression [Trial 4298a, HMAYAa] www.clinicalstudyresults.org\/documents\/company-study_887_0.pdf [accessed 5 October 2007, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0004|cit4","unstructured":"Demitrack MA Goldstein DJ Mallinckrodt C Lu Y Efficacy and safety of duloxetine treatment in major depression 154th Annual Meeting of American Psychiatric Association"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0005|cit5","unstructured":"Eli Lilly Duloxetine versus placebo in the treatment of major depression [Trial 3327a, HAMAQ A] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_137_0.pdf [accessed 5 October 2007, archived data on file]"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","article-title":"Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial","volume":"63","author":"Goldstein","year":"2002","journal-title":"Journal Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0007|cit7","unstructured":"Eli Lilly Duloxetine versus placebo and paroxetine in the acute treatment of major depression [Trial 4091b, HMAT B] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_139_0.pdf [accessed 5 October 2007, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0008|cit8","unstructured":"Goldstein DJ Lu Y Dekte MJ Wiltse CG Mallinckrodt C Demitrack MA Duloxetine versus paroxetine in the treatment of depression 155th Annual Meeting of American Psychiatric Association"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0009|cit9","first-page":"43","article-title":"Duloxetine in the treatment of depression: a double blind placebo controlled comparison with paroxetine","volume":"12","author":"Goldstein","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","article-title":"Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine","volume":"24","author":"Goldstein","year":"2004","journal-title":"Journal Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006533.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/S0924-977X(02)80231-0","article-title":"Duloxetine in the treatment of depression: a double blind placebo controlled comparison with Paroxetine","volume":"12","author":"Mallinckrodt","year":"2002","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0012|cit12","first-page":"1613","article-title":"Clinical evaluation of duloxetine in the treatment of major depressive disorder placebo and paroxetine controlled double-blind comparative study","volume":"12","author":"Higuchi","year":"2009","journal-title":"Japanese Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0013|cit13","unstructured":"Eli Lilly Duloxetine versus placebo in the treatment of major depression [Trial 3327b, HMAQ B] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_138_0.pdf [accessed 5 October 2007, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0014|cit14","unstructured":"Eli Lilly Duloxetine versus placebo and paroxetine in the acute treatment of major depression, Study Group A [Trial 4091a, HMAT A] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_170_0.pdf [accessed 5 October 2007, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0015|cit15","unstructured":"Eli Lilly Duloxetine versus venlafaxine extended release in the treatment of major depressive disorder [Trial 7999, HMCQ] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_3108_0.pdf [accessed 1 December 2010, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0016|cit16","unstructured":"Forest Laboratories Double-blind study of escitalopram in adult patients with major depressive disorder [Trial SCT-MD-23] Forest Laboratories Clinical Trial Registry [http:\/\/www.forestclinicaltrials.com\/] 2007"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00044011-200727070-00005","article-title":"Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder","volume":"27","author":"Khan","year":"2007","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0018|cit18","unstructured":"Eli Lilly Duloxetine versus paroxetine in the acute treatment of major depression [Trial 6937] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_2402_0.pdf [accessed 5 October 2007, archived data on file]"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1440-1819.2007.01666.x","article-title":"Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil","volume":"61","author":"Lee","year":"2007","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0020|cit20","unstructured":"Eli Lilly Duloxetine versus escitalopram and placebo in the treatment of patients with major depression [Trial 7978, HMCR] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_2182_0.pdf [accessed 5 October 2007, archived data on file]"},{"issue":"2","key":"10.1002\/14651858.CD006533.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006533.pub2-BIB0022|cit22","first-page":"S142","article-title":"Onset of antidepressant action and acute efficacy and safety of duloxetine versus escitalopram and placebo in the treatment of major depressive disorder","volume":"30","author":"Nierenberg","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/030079907X188107","article-title":"Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder","volume":"23","author":"Pigott","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0024|cit24","first-page":"195","article-title":"Safety and efficacy of duloxetine versus venlafaxine in major depression in Indian patients","volume":"8","author":"Badyal","year":"2006","journal-title":"JK Science"},{"issue":"2","key":"10.1002\/14651858.CD006533.pub2-BIB0025|cit25","first-page":"126","article-title":"An open label randomized, comparative, parallel group, multicentric clinical trial to evaluate the safety and efficacy of duloxetine compared to venlafaxine in patients with major depression","volume":"2","author":"Patel","year":"2011","journal-title":"Pharma Science Monitor: An International Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0026|cit26","unstructured":"Eli Lilly Duloxetine versus placebo and paroxetine in the treatment of major depression [ Trial 4298b, HMAYb] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_1618_0.pdf [accessed 5 October 2007, archived data on file]"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0028|cit28","unstructured":"Eli Lilly Duloxetine versus venlafaxine extended release in the treatment of major depressive disorder [Trial 6090, HMBU] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_3107_0.pdf [accessed 19 August 2010, archived data on file]"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jpsychires.2007.01.008","article-title":"A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder","volume":"42","author":"Perahia","year":"2008","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0030|cit30","unstructured":"Pfizer A multicenter, randomized, double-blind, placebo-controlled, duloxetine-referenced, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (50mg, 100mg) of desvenlafaxine sustained-release tablets in adult outpatients with major depressive disorder [results] ClinicalTrials.gov 2012. http:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00384033"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0032|cit32","unstructured":"Wyeth Final report: a multicenter, randomized, double-blind, placebo-controlled, duloxetine-referenced, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (50 mg, 100 mg) of desvenlafaxine sustained release tablets in adult outpatients with major depressive disorder. Synopsis based on final report. (Protocol 3151A1-335) [NCT00384033] Clinicalstudyresults.org [www.clinicalstudyresults.org] 2008 [accessed 28 March 2011, archived data on file]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0033|cit33","unstructured":"H Lundbeck A\/S A double-blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with major depressive disorder [Trial 10990] http:\/\/www.lundbecktrials.com\/Data\/PDFs\/10990_CTRS_Final%20for%20upload_28Aug2008.pdf"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1185\/030079907X210732","article-title":"A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder","volume":"23","author":"Wade","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD006533.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/00019053-200826110-00008","article-title":"Escitalopram and duloxetine in major depressive disorder: A pharmacoeconomic comparison using UK cost data","volume":"26","author":"Wade","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0036|cit36","first-page":"195","article-title":"Safety and efficacy of duloxetine versus venlafaxine in major depression in Indian patients","volume":"8","author":"Badyal","year":"2006","journal-title":"K Science"},{"issue":"9","key":"10.1002\/14651858.CD006533.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jpsychires.2008.10.015","article-title":"Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder","volume":"43","author":"Herrera-Guzman","year":"2009","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0038|cit38","first-page":"1595","article-title":"Clinical evaluation of duloxetine in the treatment of major depressive disorder: Superiority of study of 40 mg\u00a0 and 60 mg versus 5 mg","volume":"12","author":"Higuchi","year":"2009","journal-title":"Rinsho Seishin Yakuri"},{"issue":"5","key":"10.1002\/14651858.CD006533.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/11319200-000000000-00000","article-title":"Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies","volume":"33","author":"Brunton","year":"2010","journal-title":"Drug Safety: an international journal of medical toxicology and drug experience"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0040|cit40","unstructured":"Eli Lilly A double-blind, placebo- and clomipramine-controlled study in duloxetine patients with major depression [Trial 1126, HMAI] http:\/\/www.clinicalstudyresults.org\/documents\/company-study_4148_0.pdf [accessed 1 December 2010, archived data on file]"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0b013e3282ffdedc","article-title":"Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials","volume":"23","author":"Lam","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/YIC.0b013e32833948d8","article-title":"Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis","volume":"25","author":"Lam","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0043|cit43","first-page":"1533","article-title":"Clinical evaluation of duloxetine in the treatment of depression and depressive state: Mianserin-controlled double-blind comparative study","volume":"12","author":"Murasaki","year":"2009","journal-title":"Rinsho Seishin Yakuri"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0044|cit44","first-page":"1517","article-title":"Clinical evaluation of duloxetine in the treatment of depression and depressive state: Imipramine-controlled double-blind comparative study","volume":"12","author":"Murasaki","year":"2009","journal-title":"Rinsho Seishin Yakuri"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0045|cit45","unstructured":"Eli Lilly Boehringer Ingelheim Pharmaceuticals TRY FIRST: A 12-week, randomized, open-label trial of duloxetine versus generic SSRIs in the treatment of a severe depressive episode [NCT00666757] ClinicalTrials.gov 2008. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00666757"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/YIC.0b013e32834ce11b","article-title":"A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode","volume":"27","author":"Martinez","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0047|cit47","unstructured":"Eli Lilly Comparison of two different treatment strategies in patients with major depressive disorder not exhibiting improvement on escitalopram treatment: early vs. delayed intervention strategy [NCT00810068; F1J-EW-HMGD; EU 2008-002319-42] ClinicalTrials.gov 2008. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00810069"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jpsychires.2007.01.008","article-title":"A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder","volume":"42","author":"Perahia","year":"2008","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0049|cit49","first-page":"34","article-title":"Early vs. delayed switch to duloxetine in patients with major depressive disorder not exhibiting early improvement with escitalopram: A double-blind randomized study","volume":"14","author":"Romera","year":"2010","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0050|cit50","unstructured":"Asnis G Tsai J Mao Y Fixed-dose comparison of escitalopram and duloxetine in severely depressed patients Poster presented at Collegium Internationale Neuro-Psychopharmacologicum XXVI; July 15, 2008; Munich, Germany 2008"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0051|cit51","unstructured":"Forest Laboratories Fixed dose comparison of escitalopram to an active comparator in severely depressed patients [Trial SCT-MD-39] Forset Laboratories Clinical Trial Registry [www.forestclinicaltrials.com] 2006"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0052|cit52","first-page":"321","article-title":"Duloxetine versus venlafaxine in the treatment of unipolar and bipolar depression","volume":"161","author":"Serafini","year":"2010","journal-title":"Clinica Terapeutica"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0053|cit53","first-page":"1549","article-title":"Clinical evaluation of duloxetine in the treatment of depression and depressive state: Trazodone-controlled double-blind comparative study","volume":"12","author":"Tsutsui","year":"2009","journal-title":"Rinsho Seishin Yakuri"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0054|cit54","unstructured":"Joubert AF du Plessis AD Faries D Gagiano CA High Placebo response rate versus clinical impression with the new antidepressant Duloxetine Sith World Congress of Biological Psychiatry"},{"issue":"(Suppl 3)","key":"10.1002\/14651858.CD006533.pub2-BIB0055|cit55","first-page":"S390","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment [conference abstract]","volume":"21","author":"Baldwin","year":"2011","journal-title":"European Neuropsychopharmacology [abstracts of the 24th Congress of the European College of Neuropsychopharmacology, ECNP; 2011 Sept 3-7, Paris France]"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Baldwin DS Loft H Dragheim M A randomised, double-blind, placebo controlled,duloxetine-referenced, fixed-dose study of threedosages of Lu AA21004 in acute treatment of majordepressive disorder (MDD) European Neuropsychopharmacology 2011 doi:10.1016\/j.euroneuro.2011.11.008","DOI":"10.1016\/S0924-977X(11)70627-7"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0057|cit57","unstructured":"H Lundbeck A\/S\u00a0 A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of major depressive disorder [NCT00635219] ClinicalTrials.gov 2008. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00635219"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0058|cit58","unstructured":"H Lundbeck A\/S A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, fixed-dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder [NCT00672620] ClinicalTrials.gov 2008. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00672620"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0059|cit59","unstructured":"H Lundbeck A\/S Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in elderly patients [NCT00811252] ClinicalTrials.gov 2008. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00811252"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0061|cit61","unstructured":"AstraZeneca A phase IIa, multi-centre, randomized, double-blind, double-dummy, active and placebo controlled, parallel group study to assess the effectiveness and safety of AZD2066 after 6 weeks of treatment in patients with major depressive disorder - D0475C00020. [NCT01145755] ClinicalTrials.gov 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01145755"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0062|cit62","unstructured":"Servier Laboratories Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg\/day) over a 6-month treatment period in patients with major depressive disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg\/day).Twenty-four weeks of treatment. [Servier Trial CL3-20098-062; EudraCT Number: 2008-004642-92] EU Clinical Trials Register [www.clinicaltrialsregister.eu\/ctr-search\/] 2009"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0063|cit63","unstructured":"H Lundbeck A\/S A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg\/Day) in the acute treatment of adult patients with major depressive disorder [NCT01140906] ClinicalTrials.gov 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01140906 2010"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0064|cit64","unstructured":"Takeda A phase 3, randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder [NCT01153009] ClinicalTrials.gov 2010 http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01153009 2010"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0065|cit65","unstructured":"AstraZeneca A phase IIb, randomized, double-blind, placebo-controlled, active controlled, parallel group, multicenter study to assess the safety and efficacy of 2 fixed dose groups of TC-5214 (S-mecamylamine) as monotherapy treatment in patients with major depressive disorder who exhibit an inadequate response to antidepressant therapy [NCT01288079; D4131C00001; EU 2010-023816-15] http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01288079"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"7066","key":"10.1002\/14651858.CD006533.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/026988110001400101","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines","volume":"14","author":"Anderson","year":"2000","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0069|cit69","article-title":".","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD006533.pub2-BIB0070|cit70","first-page":"1","article-title":"Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association","volume":"157","author":"American Psychiatric Association","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0071|cit71","volume-title":"American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006","author":"American Psychiatric Association","year":"2006"},{"issue":"2","key":"10.1002\/14651858.CD006533.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.jcp.0000115665.45074.0d","article-title":"\"Wish bias\" in antidepressant drug trials?","volume":"24","author":"Barbui","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0073|cit73","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrn1629","article-title":"Is mood chemistry?","volume":"6","author":"Castr\u00e9n","year":"2005","journal-title":"Nature Reviews Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004185.pub2","article-title":"Fluoxetine versus other types of pharmacotherapy for depression","author":"Cipriani","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4088\/JCP.v67n0601","article-title":"Are all antidepressants really the same? The case of fluoxetine: A systematic review","volume":"67","author":"Cipriani","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"746\u201358","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other antidepressive agents for depression","author":"Cipriani","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006533.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006532.pub2","article-title":"Escitalopram versus other antidepressive agents for depression","author":"Cipriani","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006533.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1121189X00000968","article-title":"Why internal and external validity of experimental studies are relevant for clinical practice?","volume":"18","author":"Cipriani","year":"2009","journal-title":"Epidemiology and Psychiatric Sciences"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1121189X00000452","article-title":"What is a randomised controlled trial?","volume":"18","author":"Cipriani","year":"2009","journal-title":"Epidemiologia e Psichiatria Sociale"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006534.pub2","article-title":"Citalopram versus other anti-depressive agents for depression","author":"Cipriani","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD006533.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-004-0810-8","article-title":"Are we going to increase the use of antidepressants up to that of benzodiazepines?","volume":"60","author":"Ciuna","year":"2004","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0087|cit87","article-title":"Depression in primary care: Vol 2","volume-title":"Treatment of Major Depression, Clinical Practice Guideline, Number 5, AHCPR Publication No. 93-0551","author":"Depression Guideline","year":"1993"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0088|cit88","first-page":"259","article-title":"Depression","volume-title":"Handbook of Assessment and Treatment Planning for Psychological Disorders","author":"Dozois","year":"2004"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00023210-200721070-00004","article-title":"Duloxetine: a review of its use in the treatment of major depressive disorder","volume":"21","author":"Frampton","year":"2007","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7371","key":"10.1002\/14651858.CD006533.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/bmj.325.7371.991","article-title":"Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review","volume":"325","author":"Furukawa","year":"2002","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD006533.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jama.297.5.468-b","article-title":"Association between unreported outcomes and effect size estimates in Cochrane meta-analyses","volume":"297","author":"Furukawa","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD006533.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2165\/11318930-000000000-00000","article-title":"The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis","volume":"32","author":"Gartlehner","year":"2009","journal-title":"Drug Safety"},{"issue":"7","key":"10.1002\/14651858.CD006533.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e11895","DOI":"10.1371\/journal.pone.0011895","article-title":"Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review","volume":"5","author":"Gartlehner","year":"2010","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0099|cit99","volume-title":"Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"690\u20133","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(95)71666-8","article-title":"Global Assessment of Functioning - a modified scale","volume":"36","author":"Hall","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-143-6-200509200-00006","article-title":"Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder","volume":"143","author":"Hansen","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD006533.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0105|cit105","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.npp.1300059","article-title":"Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports","volume":"28","author":"Khan","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"7400","key":"10.1002\/14651858.CD006533.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006533.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000448.pub3","article-title":"St John's wort for major depression","author":"Linde","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD006533.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cct.2004.09.002","article-title":"An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia","volume":"25","author":"Montgomery","year":"2004","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003491.pub2","article-title":"Antidepressants for depressed elderly","author":"Mottram","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0165-0327(02)00120-9","article-title":"Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS)","volume":"77","author":"M\u00fcller","year":"2003","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006529.pub2","article-title":"Milnacipran versus other antidepressive agents for depression","author":"Nakagawa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0116|cit116","volume-title":"Depression: management of depression in primary and secondary care (http:\/\/guidance.nice.org.uk\/CG90)","author":"National Institute for Clinical Excellence","year":"2010"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006114.pub2","article-title":"Fluvoxamine versus other anti-depressive agents for depression.","author":"Omori","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006533.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer's guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006533.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1176\/appi.ajp.162.10.1957","article-title":"Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry","volume":"162","author":"Perlis","year":"2005 Oct","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006533.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/070674370404900905","article-title":"Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine","volume":"49","author":"Procyshyn","year":"2004","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"82\u201393","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: to whom do the results apply?","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD006533.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"408\u201312","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD006533.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Archives General Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0124|cit124","volume-title":"Essential Psychopharmacology","author":"Stahl","year":"2000"},{"issue":"11","key":"10.1002\/14651858.CD006533.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"Journal of clinical epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD006533.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1017\/S0033291797005205","article-title":"Symptom profiles of depression among general medical service users compared with specialty mental health service users","volume":"27","author":"Suh","year":"1997","journal-title":"Psychological Medicine"},{"issue":"11","key":"10.1002\/14651858.CD006533.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archpsyc.63.11.1217","article-title":"Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis","volume":"63","author":"Taylor","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","article-title":"Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression","volume":"25","author":"Thase","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006533.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short form health survey (SF-36)","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0131|cit131","volume-title":"SF-12: How to Score the SF-12.Physical and Mental Health Summary Scales","author":"Ware","year":"1998"},{"issue":"12","key":"10.1002\/14651858.CD006533.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006528.pub2","article-title":"Mirtazapine versus other antidepressive agents for depression","author":"Watanabe","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0133|cit133","volume-title":"The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0134|cit134","unstructured":"World Health Organization WHO Collaborative Centre for Drug Statistics Methodology http:\/\/www.whocc.no\/atcddd\/"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0135|cit135","unstructured":"WHO Collaborative Centre for Drug Statistics Methodology ATC\/DDD Index 2009 http:\/\/www.whocc.no\/atcddd\/ 2009"},{"issue":"12","key":"10.1002\/14651858.CD006533.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties","volume":"46","author":"WHOQOL Group","year":"1998","journal-title":"Social Science and Medicine"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the nation outcome scales (HoNOS): Research and development","volume":"172","author":"Wing","year":"1998","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006533.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-0348-8183-8_5","article-title":"Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?","volume":"58","author":"Wong","year":"2002","journal-title":"Progres in Drug Research"},{"issue":"7644","key":"10.1002\/14651858.CD006533.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006533.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:05:18Z","timestamp":1729469118000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006533.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":139,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006533.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}